Obesity evidence dossier
WVE-007
The main development question is whether the visceral-fat signal can support a defined body-composition phenotype, add-on use with incretins, or post-incretin maintenance.
Total weight loss
Not reported
Early clinical development
Placebo-adjusted
Not reported
Difference from placebo in the same study when reported.
Study context
INHBE silencing program/Adults living with overweight or obesity/Phase 1b/2a; early clinical program/Early clinical follow-up
Baseline: Body-composition biology rather than total weight loss is the main lens
Ranked result & calculation
Trial inputs have not yet been verified for this scoring method.
Evidence
Benchmark read
Phase 1 INLIGHT updates reported visceral-fat reduction, total-fat reduction, lean-mass preservation, and waist-circumference improvement after single-dose WVE-007 (placebo-adjusted visceral-fat change ~14% at 6 months after a single 240 mg dose in participants with mean BMI near 32). This program is not ranked by total body-weight loss; the rationale is selective fat-distribution biology.
Diabetes data
The Phase 2a portion is designed to study higher-BMI patients with comorbidities, with and without type 2 diabetes; those cohorts should be interpreted separately from otherwise healthy overweight/obesity cohorts.
Primary lens
Visceral fat
Tracked separately because the patient question is metabolic fat distribution, muscle preservation, and long-term cardiometabolic risk, not only total body-weight change.
Safety
Side effects and cautions
Discontinuation read
Human tolerability data are limited and should not be compared with large incretin trials.
Common side effects
Wave has described WVE-007 as generally safe and well tolerated in early clinical data; larger and longer trials need to define injection-site, hepatic, muscle-function, and oligonucleotide-class risks.
Main cautions
Not approved; early cohorts are small, endpoints are body-composition heavy, and Phase 2a needs to show whether visceral-fat and lean-mass signals translate to clinically meaningful cardiometabolic benefit.
Upcoming catalyst
What to watch next
Phase 2a monotherapy data in higher-BMI patients, plus planned incretin add-on and post-incretin maintenance trials.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06842186
Phase 1
A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
Wave Life Sciences Ltd.
Non-diabetic obesity
Feb 10, 2026
NCT06700538
Phase 2
Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
Arrowhead Pharmaceuticals
Type 2 diabetes / obesity
Dec 17, 2025